Navigation Links
EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus
Date:12/9/2013

The European Association for the Study of the Liver (EASL) today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection (HCV) (1). The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.

It is estimated that approximately 160 million individuals, i.e. 2.35% of the world's population, are chronically infected with HCV. In the European Union alone, between 7.3 and 8.8 million people are infected with HCV, double the previous estimate made in 1997. The prevalence varies across the region with higher rates seen in the south and the east, making HCV a critical area of attention for hepatologists as one fifth of HCV-infected patients are at risk of developing cirrhosis or liver cancer (2).

HCV CPG co-chair reviewer and consultant hepatologist at Queen Elizabeth Hospital, Birmingham, Professor David Mutimer said: "As our understanding of HCV increases and therapies evolve, more complex treatment strategies are necessary to achieve the primary goal of curing the infection.

"Since EASL published the last HCV CPG in 2011, two protease inhibitors have been approved for use in patients infected with HCV genotype 1. These first-generation direct-acting antivirals are the first of many direct acting antiviral drugs which will revolutionise treatment for HCV patients, including those who failed to respond to previous therapies. The new guidelines provide essential information on the recommended use of these newly licensed drugs to help prescribers deliver optimal care for their HCV patients."

Based on a systematic review of existing literature, the CPGs provide best practice recommendations on a number of key areas:

  • Current standard of care and developing therapies
  • Diagnosis of acute and chronic hepatitis C
  • Goals
    '/>"/>

Contact: Courtney Lock
easlpressoffice@cohnwolfe.com
44-207-331-5317
European Association for the Study of the Liver
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
2. Elseviers Maturitas publishes position statement on fertility preservation
3. Genetics in Medicine publishes special issue dedicated to genomics in electronic health records
4. Journal of Spinal Cord Medicine publishes special issue on assistive technology
5. American Academy of Microbiology publishes West Nile virus report
6. Reproductive BioMedicine Online publishes study on assisted reproduction
7. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
8. Leading RSV researcher publishes work at Le Bonheur Childrens
9. PeerJ publishes its first articles
10. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
11. Professor publishes on first-ever imaging of cells growing on spherical surfaces
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus
(Date:7/27/2014)... date, researchers from the U.K. provide national, regional, and ... (HCV). Findings published in Hepatology, a journal of the ... that genotype 1 is the most prevalent worldwide, with ... in East Asia. Genotype 3, at just over 54 ... genotypes 2, 4, 6, and 5. , Despite ...
(Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
(Date:7/27/2014)... scientists at Barts Cancer Institute have found that targeting ... significantly more effective, according to research published in ... Institute, part of Queen Mary University of London, have ... signals the body to repair itself after chemotherapy or ... the researchers removed FAK from blood vessels that grew ...
Breaking Biology News(10 mins):Hepatitis C virus genotype 1 is most prevalent worldwide 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2
... threat, city and country birds do not react in the ... a new study, urban birds have changed their anti-predator behaviour ... with a predator, its only objective is to escape. However, ... their countryside counterparts, despite being from the same species. Urbanisation ...
... backbone of our modern economy. Nearly every aspect of life ... it is not just the lights that go out. In ... working. Even telephones, radios and televisions become paralyzed. If the ... gas and fuel and the functioning of respirators at intensive ...
... advances in the new and developing field of restoration ... deltas from an array of threats, Indiana University Bloomington ... Nature Geoscience . The commentary, published this week ... is disappearing from river deltas at alarming rates. And ...
Cached Biology News:City birds adapt to their new predators 2Dealing with power outages more efficiently 2Geologist calls for advances in restoration sedimentology 2
(Date:7/28/2014)... According to a new market ... Medicine (Bone and Joint) Market (By Technology - ... Applications - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic ... Analysis, Size, Share, Growth, Trends and Forecast, 2013 ... joint) market was valued at USD 2.6 billion ...
(Date:7/28/2014)... July 28, 2014 /PRNewswire/ -   JOLT , a ... companies to join its growing portfolio of startups. Next-level ... Toronto,s JOLT accelerator, and Cohort four ... roster. Since its launch in July ... raised  $7.5M of financing. Now at 23 investments, JOLT,s ...
(Date:7/28/2014)... 28, 2014 Immunomic Therapeutics, Inc. (ITI) ... further develop potential treatments for glioblastoma multiforme (GBM), the ... with their patented vaccine platform, LAMP-vax. , The ... based on the work of John H. Sampson, MD, ... Preston Robert Tisch Brain Tumor Center at Duke University ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 It’s ... their GI Bill benefits to further their post-secondary education are ... says a study released this year. And according to an ... of this shortfall is veteran students’ uninformed choice of college ... , The details of the study: Some 51.7 percent of ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4
... revenue increase as broad corporate changes are ... ... Nanotech, Inc. (OTC,Bulletin Board: AVNA) today reported financial results for its ... fiscal,period since the Company refocused its business model from managing the,development ...
... 16 Immunosyn,Corporation (OTC Bulletin Board: IMYN), a ... and distribution rights to,the biopharmaceutical SF-1019 from its ... the quarter ending March 31, 2008., For ... incurred $175,632.00,in general and administrative expenses and $13,393.00 ...
... in the ... ... BSX ) today announced U.S. Food and Drug Administration,(FDA) approval of ... defibrillators (CRT-D) and cardiac,resynchronization therapy pacemakers (CRT-P), both of which treat ...
Cached Biology Technology:Advance Nanotech Reports First Quarter 2008 Financial Results 2Advance Nanotech Reports First Quarter 2008 Financial Results 3Advance Nanotech Reports First Quarter 2008 Financial Results 4Advance Nanotech Reports First Quarter 2008 Financial Results 5Advance Nanotech Reports First Quarter 2008 Financial Results 6Advance Nanotech Reports First Quarter 2008 Financial Results 7Advance Nanotech Reports First Quarter 2008 Financial Results 8Advance Nanotech Reports First Quarter 2008 Financial Results 9Advance Nanotech Reports First Quarter 2008 Financial Results 10Immunosyn Corporation Files 10-Q 2Immunosyn Corporation Files 10-Q 3Boston Scientific Announces FDA Approval of New Heart Failure Lead 2Boston Scientific Announces FDA Approval of New Heart Failure Lead 3Boston Scientific Announces FDA Approval of New Heart Failure Lead 4
... active ingredient in Molecular Probes. SlowFadeAntifade ... to act as a free radical ... Our original SlowFade formulation (S-2828) was ... of fluorescein to almost zero (Figure ...
b6-2A12...
... in this kit are prepared with pure ... Biochains Mitochondria Isolation Kit is designed to ... fast and easy way. One kit is ... isolations (enriching mitochondria from 10 20 ...
... The Freedom EVOlyzer is Tecans new ... automated microplate processing. Freedom EVOlyzer is a ... includes state-of-the art reader, washer and incubation ... software. The Freedom EVOlyzer is available in ...
Biology Products: